18 Jun ENNAID THERAPEUTICS PARTNERS EXCLUSIVELY WITH STRIDES TO MANUFACTURE LIFE-SAVING ORAL COVID-19 TABLET
Full posting found HERE
GEORGIA, US and BENGALURU, INDIA – June 14, 2021 – Strides Pharma Science Limited today announced that its step-down wholly-owned subsidiary, Strides Pharma Global Pte. Limited, Singapore has entered into an exclusive partnership with Ennaid Therapeutics, a global, pharmaceutical company, to produce an oral, repurposed medication to treat mild, moderate and asymptomatic cases of COVID-19.
Through Ennaid’s partnership with discovery scientists at Universidad Católica de Murcia (UCAM), the company identified a therapeutic target to treat COVID-19 using artificial intelligence drug discovery platforms. Initial tests show antiviral activity effective against SARS CoV-2, the virus that causes COVID-19, by inhibiting 90% of the virus’ replication in vitro studies. These results are so compelling that Ennaid is now seeking emergency authorization from the FDA in the United States as well as approval for compassionate use in India. Strides will be the exclusive manufacturing partner to Ennaid for the product.
Ennaid’s CEO, Darnisha Harrison, commented on the impact of the epidemic and partnership with Strides:“The magnitude of human loss in India due to COVID-19 compelled Ennaid India Private Limited to partner with Strides Pharma extending critical resources to aid its government. We are honored to join forces with another India-based company to bring hope and healing at a time when it’s critically needed. Since the drug was previously approved by the FDA for other indications, it has already been proven safe in humans. What we have will not only bring much needed relief to India but to patients around the world. With more than 30 million people infected with COVID-19 in America and over 100 million in the world, Harrison says a drug that treats mild to moderate symptoms and helps block replication of the virus is a top priority.”
Dr R Ananthanarayanan, Managing Director and Group CEO, Strides, stated:“We are pleased to partner with Ennaid as an exclusive manufacturer of its oral repurposed medication to treat mild, moderate and asymptomatic cases of COVID-19. At Strides we are committed in our fight against COVID-19 and are working on creating a portfolio of products to aid COVID treatment and supportive care. Partnership with Ennaid is part of our initiative to provide quality and affordable treatment to the global patient pool impacted by COVID-19.”
Ennaid is a global biopharmaceutical company based in the United States, with subsidiaries in Australia, the United Kingdom, and India. Ennaid is developing a robust pipeline of therapeutics to treat COVID-19 and other deadly, infectious diseases affecting humans and animals worldwide using artificial intelligence drug discovery platforms. The company’s immediate focus is developing an antiviral treatment for COVID-19, but also has a rich mosquito-borne disease pipeline of patented, new therapeutics targeting dengue virus, Zika virus, West Nile virus, as well as a patented, repurposed drug that may treat advanced-stage colorectal cancer.
Ennaid has two promising digital health products under development. One is a software-based diagnostic that detects and measures traumatic brain injuries, such as concussions; the other is a clinical trial reporting software with telemedicine features. The Five Pillars of Ennaid are coronavirus, infectious diseases, oncology, digital health, and animal health. For more details, please visit https://ennaidthera.com
Strategically located in Murcia, Spain, with a Campus of more than 16,000 students and around 1,000 professors, UCAM is expanding worldwide to make their main objectives a reality: to promote a high-quality university education, with a representative presence in all continents. UCAM has a friendly and international environment in a privileged Mediterranean framework that collaborates with universities from all corners of the planet, at every educational level: research, students and professors exchange and create international undergraduate and master’s programs in all specialties. The computational drug design group is formed by the scientists Horacio Pérez-Sánchez, José Pedro Cerón-Carrasco, Jorge Peña-García, Alfonso Pérez-Garrido and Antonio Jesús Banegas Luna.
Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bengaluru, India. The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy along with an institutional business to service donor-funded markets. The Company’s global manufacturing sites are located in India (Chennai, Puducherry and two locations in Bengaluru), Singapore, Italy (Milan), Kenya (Nairobi) and the United States (Florida). The Company focusses on “difficult to manufacture” products that are sold in over 100 countries. Additional information is available at the Company’s website at www.strides.com